张继红 1罗涛 1李小妹 2石孟琼 3熊兴军 4李小琴 2冯旻璐 2许海燕 2杨文雁 3覃慧林1
作者信息
- 1. 三峡大学中医医院&宜昌市中医医院消化内科,宜昌443001,湖北
- 2. 三峡大学生物与制药学院天然产物研究与利用湖北省重点实验室,宜昌443002,湖北
- 3. 三峡大学医学院基础医学实验中心,宜昌443002,湖北
- 4. 长阳县中医医院药剂科,长阳443501,湖北
- 折叠
摘要
Abstract
AIM: To investigate the clinical effect Muguasantie combined with mesalazine on the clinical efficacy, inflammatory and intestinal barrier protective factors of ulcerative colitis. METHODS:Ninety patients with ulcerative colitis were randomly divided into the control group and treatment group, with 45 cases in each group. The control group was given mesalazine 1. 0 g each time, while the treat-ment group was given mesalazine plus Muguasantie 0. 375 g each time, 3 times a day for 8 consecutive weeks. The clinical efficacy, the adverse reaction incidence, clinical symptom and sign score, disease activity index ( DAI) score, colonoscopy score and histopathology score of the two groups were com-pared; the contents of tumor necrosis factor ( TNF)-α, interleukin (IL)-1β, IL-6, interferon(IFN)-γ, IL-4, IL-10 in the peripheral blood, and myeloper-oxidase ( MPO) activity, locked small band protein 1 ( ZO1 ) , calcium adhesion protein E ( E-cadher-in) , occludin, mucin 2 ( MUC2 ) , and intestinal trifolium factor ( TFF3) mRNA expressions in colon-ic mucosa were detected, respectively. RESULTS:After treatment, the total effective rate of the treat-ment group (86. 67% ) was significantly higher than that of the control group (66. 67% ) , and the inci-dence of adverse reactions was significantly lower than that of the control group ( P < 0. 01 ) ; the symptom and sign score, the DAI score, colonosco-py score and histopathology score were significantly lower than those of the control group ( P<0. 05 or P<0. 01, respectively); the contents of TNF-α, IL-1β, IL-6, IFN-γ in the peripheral blood, and MPO activity in colonic mucosa were significantly lower, and IL-4 and IL-10 was significantly higher than those of the control group ( P <0. 05 or P <0. 01, respectively); the mRNA expressions of ZO1, E-cadherin, occludin, MUC2 and TFF3 in the colonic mucosa were significantly up-regulated than those of the control group ( P <0. 05 or P <0. 01, respec-tively ) . CONCLUSION: Muguasantie combined with mesalazine has good therapeutic effect and low-er side effect on patients with ulcerative colitis. Its mechanism is related to inhibiting the productions of pro-inflammatory factors, restoring the balance be-tween pro-inflammatory and anti-inflammatory factors and up-regulating the expression of intestinal muco-sal barrier protective factors.关键词
木瓜三萜/溃疡性结肠炎/临床疗效/炎症因子/黏膜屏障保护因子Key words
Muguasantie/ulcerative colitis/clinical efficacy/inflammatory factors/intestinal barrier protective factors分类
医药卫生
